tbuckley/cabot-search huggingface dataset:
Usefulness of Regional Electrocardiogram to Predict the Responder in Patients with Cardiac Resynchronization
Authors: Onuma Yoshimasa, Chiba Yuta, Onishi Yoshimi, Kawasaki Shirou, Munetsugu Yumi, Kikuchi Miwa, Ito Hiroyuki, Onuki Tatsuya, Miyoshi Fumito, Minoura Yoshino, Watanabw Norikazu, Adachi Taro, Asano Taku, Tanno Kaoru, Kobayashi Youichi
Journal: Circulation (2014)
Hierarchical ultrastructure: An overview of what is known about tendons and future perspective for tendon engineering
Authors: Shichen Zhang, Wei Ju, Xiaoyi Chen, Yanyan Zhao, Lingchong Feng, Zi Yin, Xiao Chen
Journal: Bioactive Materials (2021)

Abnormal tendons are rarely ever repaired to the natural structure and morphology of normal tendons. To better guide the repair and regeneration of injured tendons through a tissue engineering method, it is necessary to have insights into the internal morphology, organization, and composition of natural tendons. This review summarized recent researches on the structure and function of the extracellular matrix (ECM) components of tendons and highlight the application of multiple detection methodologies concerning the structure of ECMs. In addition, we look forward to the future of multi-dimensional biomaterial design methods and the potential of structural repair for tendon ECM components. In addition, focus is placed on the macro to micro detection methods for tendons, and current techniques for evaluating the extracellular matrix of tendons at the micro level are introduced in detail. Finally, emphasis is given to future extracellular matrix detection methods, as well as to how future efforts could concentrate on fabricating the biomimetic tendons.
Pharmacodynamic Monitoring of Targeted Therapy with Midostaurin By Plasma Inhibitor Activity (PIA) Analysis in FLT3 -ITD Positive AML Patients Enrolled in the AMLSG16-10 Trial: A Study of the AML Study Group (AMLSG)
Authors: Frauke Theis, Peter Paschka, Daniela Weber, Verena I. Gaidzik, Lars Bullinger, Gudrun Göhring, Helmut R. Salih, Felicitas Thol, Michael Heuser, Thomas Schroeder, Hans Jürgen Salwender, Joerg Westermann, Walter Fiedler, Katharina S. Götze, Heinz A. Horst, Gerald Wulf, Michael Lübbert, Dominik Wolf, Thomas Kindler, Mark Ringhoffer, Doris M. Kraemer, Richard F. Schlenk, Jürgen Krauter, Arnold Ganser, Hartmut Döhner, Konstanze Döhner
Journal: Blood (2017)
neuronal pentraxin 2はAMPA選択的グルタミン酸受容体4を活性化することによって腎明細胞癌を支持する
Authors: A Von Roemeling Christina, C Radisky Derek, A Marlow Laura, J Cooper Simon, K Grebe Stefan, Z Anastasiadis Panagiotis, W Tun Han, A Copland John
Journal: Cancer Research (2014)
STING agonist loaded lipid nanoparticles overcome anti-PD-1 resistance in melanoma lung metastasis via NK cell activation
Authors: Takashi Nakamura, Takanori Sato, Rikito Endo, Shun Sasaki, Naomichi Takahashi, Yusuke Sato, Mamoru Hyodo, Yoshihiro Hayakawa, Hideyoshi Harashima
Journal: Journal for ImmunoTherapy of Cancer (2021)

Background Resistance to an immune checkpoint inhibitor (ICI) is a major obstacle in cancer immunotherapy. The causes of ICI resistance include major histocompatibility complex (MHC)/histocompatibility locus antigen (HLA) class I loss, neoantigen loss, and incomplete antigen presentation. Elimination by natural killer (NK) cells would be expected to be an effective strategy for the treatment of these ICI-resistant tumors. We previously demonstrated that a lipid nanoparticle containing a stimulator of an interferon gene (STING) agonist (STING-LNP) efficiently induced antitumor activity via the activation of NK cells. Thus, we evaluated the potential of reducing ICI resistance by STING-LNPs. Methods Lung metastasis of a B16-F10 mouse melanoma was used as an anti-programmed cell death 1 (anti-PD-1)-resistant mouse model. The mice were intravenously injected with the STING-LNP and the mechanism responsible for the improvement of anti-PD-1 resistance by the STING-LNPs was analyzed by RT-qPCR and flow cytometry. The dynamics of STING-LNP were also investigated. Results Although anti-PD-1 monotherapy failed to induce an antitumor effect, the combination of the STING-LNP and anti-PD-1 exerted a synergistic antitumor effect. Our results indicate that the STING-LNP treatment significantly increased the expression of CD3, CD4, NK1.1, PD-1 and interferon (IFN)-γ in lung metastases. This change appears to be initiated by the type I IFN produced by liver macrophages that contain the internalized STING-LNPs, leading to the systemic activation of NK cells that express PD-1. The activated NK cells appeared to produce IFN-γ, resulting in an increase in the expression of the PD ligand 1 (PD-L1) in cancer cells, thus leading to a synergistic antitumor effect when anti-PD-1 is administered. Conclusions We provide a demonstration to show that a STING-LNP treatment can overcome PD-1 resistance in a B16-F10 lung metastasis model. The mechanism responsible for this indicates that NK cells are activated by stimulating the STING pathway which, in turn, induced the expression of PD-L1 on cancer cells. Based on the findings reported herein, the STING-LNP represents a promising candidate for use in combination therapy with anti-PD-1-resistant tumors.
Paediatric non-rhabdomyosarcoma soft tissue sarcomas: the prospective NRSTS 2005 study by the European Pediatric Soft Tissue Sarcoma Study Group (EpSSG)
Authors: Andrea Ferrari, Max M van Noesel, Bernadette Brennan, Ilaria Zanetti, Nadege Corradini, Michela Casanova, Pablo Berlanga, Johannes H M Merks, Rita Alaggio, Stefan Schifflers, Gema L Ramirez-Villar, Chiara Giraudo, Gabriela Guillen Burrieza, Akmal Safwat, Gianni Bisogno, Gian Luca De Salvo, Daniel Orbach
Journal: The Lancet Child & Adolescent Health (2021)
Real World Data: Delay on Symptoms and Diagnosis Recognition Associated with Relapse and Death in Thrombocytopenic Thrombotic Purpura (PTT)
Authors: Marcus Vinicius Ludwig, Laura Fogliatto, Kamila Grokoski, Lucia Silla, Paz Aparecida Alessandra, Liane Esteves Daudt, Carolina Fusinato Molin, Giane Durigon, Arturo Freja, Alini Vargas, Leo Sekine
Journal: Blood (2017)
Abstract 11227: Single-cell Transcriptomes Identify Abnormal Endothelial Subpopulation in Pulmonary Arterial Hypertension
Authors: Zhiyu Dai, Jingbo Dai, You-Yang Zhao
Journal: Circulation (2019)

Introduction: Pulmonary arterial hypertension (PAH) is a disaster disease characterized by obliterative vascular remodeling and persistent increase of vascular resistance, leading to right heart fa...
A multi-omics investigation of the composition and function of extracellular vesicles along the temporal trajectory of COVID-19
Authors: Sin Man Lam, Chao Zhang, Zehua Wang, Zhen Ni, Shaohua Zhang, Siyuan Yang, Xiahe Huang, Lesong Mo, Jie Li, Bernett Lee, Mei Mei, Lei Huang, Ming Shi, Zhe Xu, Fan-Ping Meng, Wen-Jing Cao, Ming-Ju Zhou, Lei Shi, Gek Huey Chua, Bowen Li, Jiabao Cao, Jun Wang, Shilai Bao, Yingchun Wang, Jin-Wen Song, Fujie Zhang, Fu-Sheng Wang, Guanghou Shui
Journal: Nature Metabolism (2021)
Evaluation of the extended efficacy of the Dengvaxia vaccine against symptomatic and subclinical dengue infection
Authors: Henrik Salje, Maria Theresa Alera, Mary Noreen Chua, Taweewun Hunsawong, Damon Ellison, Anon Srikiatkhachorn, Richard G. Jarman, Gregory D. Gromowski, Isabel Rodriguez-Barraquer, Simon Cauchemez, Derek A. T. Cummings, Louis Macareo, In-Kyu Yoon, Stefan Fernandez, Alan L. Rothman
Journal: Nature Medicine (2021)
Comparative Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors vs Sulfonylureas in Patients With Type 2 Diabetes
Authors: Yan Xie, Benjamin Bowe, Andrew K. Gibson, Janet B. McGill, Geetha Maddukuri, Ziyad Al-Aly
Journal: JAMA Internal Medicine (2021)

In the treatment of type 2 diabetes, evidence of the comparative effectiveness of sodium-glucose cotransporter 2 (SGLT2) inhibitors vs sulfonylureas-the second most widely used antihyperglycemic class after metformin-is lacking.
Targeted Drug Delivery to the Pulmonary Endothelium Using Liposomal Nanocarriers and Red Blood Cell Super Carriers
Authors: L. Ferguson, E. Hood, T. Shuvaeva, V. Shuvaev, M. C. Basil, V. Muzykantov, J. S. Brenner
Journal: American Journal of Respiratory and Critical Care Medicine (2021)

Myriad compounds have desirable effects on specific cell subtypes but cannot be used as medications because of toxic effects on surrounding cells or organs. While nanomedicine, in particular targeted nanomedicine, has improved organ-level targeting, delivery of drug to a specific cell type remains challenging. We have previously demonstrated that red blood cells (RBC) can be used to as super-carriers that boost delivery of dual-targeted liposomes to the pulmonary endothelium such that up to 65% of the total dose is delivered to the lungs. In contrast, freely injected single-targeted liposomes deliver, at best, 25% of total dose to the lungs. These precisely designed liposomal drug carriers are coated with antibodies to both their RBC carriers and the destination target cell. We IV injected RBC-loaded dual-targeted liposomes into a murine model, allowed them to circulate for 30 minutes, then used flow cytometry to quantify liposome binding to endothelial cells and leukocytes. We found that, in addition to a > 2.5-fold increase in delivery to the lungs compared to freely injected single-targeted liposomes, there was an additional > 6-fold increase in delivery to the endothelial cell subpopulation. Specifically, the percent of endothelial cell population bound by liposomes increased from 4% to 85% using dual-targeted RBC-bound liposomes. This corresponds to an overall 55-fold increase in drug delivered to the pulmonary endothelium. As lipid-based nanocarriers such as those used in several cancer therapeutics and those used in Covid vaccines grow in popularity, targeting to specific cell populations will become increasingly important.
Abstract 5334: Association Between Hospital Process Performance and 1-Year Post-discharge Mortality in Patients With Non-ST-elevation Myocardial Infarction: Results From 36,262 Patients
Authors: Bimal R Shah, Matthew T Roe, Anita Y Chen, Karen P Alexander, Tracy Y Wang, E. Magnus Ohman, W. Brian Gibler, Eric D Peterson
Journal: Circulation (2009)

Background: While hospitals’ adherence to performance measures for evidence-based NSTEMI care has been associated with better in-hospital outcomes, its association with long-term mortality is unknown. Methods: Clinical data from CRUSADE were matched to Medicare claims, creating a longitudinal record of outcomes for patients aged &gt;=65 years. Cox proportional hazard modeling was used to examine the association between 1-year post-discharge mortality and hospital composite adherence to 9 Class I ACC/AHA guideline therapies (antiplatelet, beta-blocker, any heparin, and GP IIB/IIIA within 24 hours; antiplatelet, beta-blocker, clopidogrel, ACEI/ARB, and lipid-lowering agent at discharge). Results: Between February 19, 2003, and December 31, 2006, 36,262 NSTEMI patients treated at 268 CRUSADE hospitals were linked to Medicare data. The median hospital composite performance adherence score was 81% and varied widely (lowest to highest quartile: 73%, 79%, 83%, and 88%). Greater composite performance adherence was strongly associated with reduction in 1-year mortality. The observed 1-year mortality rate was 21%. Unadjusted mortality rates were 24%, 22%, 19%, and 19% in the lowest to highest hospital adherence score quartiles. This association persisted after adjusting for baseline clinical factors and additionally for revascularization (p&lt;0.001 between highest and lowest hospital adherence score quartiles for all hazard ratios) (Figure ). Conclusion: Hospital adherence to ACC/AHA AMI guideline therapies is strongly associated with improved long-term mortality, further supporting the use of these metrics for measuring and improving AMI. care.
Acute kidney injury in the critically ill: an updated review on pathophysiology and management
Authors: Peter Pickkers, Michael Darmon, Eric Hoste, Michael Joannidis, Matthieu Legrand, Marlies Ostermann, John R. Prowle, Antoine Schneider, Miet Schetz
Journal: Intensive Care Medicine (2021)

Acute kidney injury (AKI) is now recognized as a heterogeneous syndrome that not only affects acute morbidity and mortality, but also a patient's long-term prognosis. In this narrative review, an update on various aspects of AKI in critically ill patients will be provided. Focus will be on prediction and early detection of AKI (e.g., the role of biomarkers to identify high-risk patients and the use of machine learning to predict AKI), aspects of pathophysiology and progress in the recognition of different phenotypes of AKI, as well as an update on nephrotoxicity and organ cross-talk. In addition, prevention of AKI (focusing on fluid management, kidney perfusion pressure, and the choice of vasopressor) and supportive treatment of AKI is discussed. Finally, post-AKI risk of long-term sequelae including incident or progression of chronic kidney disease, cardiovascular events and mortality, will be addressed.
Glucocorticoid toxicity reduction with mepolizumab using the Glucocorticoid Toxicity Index
Authors: P. Jane McDowell, John H. Stone, Yuqing Zhang, Kirsty Honeyford, Louise Dunn, R. Jayne Logan, Lorcan P.A. McGarvey, Claire A. Butler, Liam G. Heaney
Journal: European Respiratory Journal (2021)

Background Reduction in glucocorticoid exposure is the primary benefit of new biologic treatments in severe asthma, but there is currently no evidence that reduction in glucocorticoid exposure corresponds to a proportionate reduction in associated toxicity. Objectives To use the validated Glucocorticoid Toxicity Index (GTI) to assess change in glucocorticoid toxicity after 12 months treatment with mepolizumab, and compare toxicity change to glucocorticoid reduction and change in patient-reported outcome measures (PROMs). Methods A longitudinal, real-world prospective cohort of 101 consecutive patients with severe asthma commenced on mepolizumab in a specialist UK regional severe asthma clinic. GTI toxicity assessment, cumulative glucocorticoid exposure and PROMs were recorded on commencing mepolizumab (V1), and after 12 months treatment (V2). Results There was significant reduction in oral glucocorticoid exposure (V1 median 4280 mg prednisolone per year (interquartile range 3083–5475 mg) versus V2 2450 mg prednisolone per year (1243–3360 mg), p&lt;0.001). Substantial improvements in individual toxicities were observed, but did not correlate with oral glucocorticoid reduction. Mean± sd GTI aggregate improvement score (AIS) was −35.7±57.8 with a wide range in toxicity change at individual patient level (AIS range −165 to +130); 70% (71 out of 101) had a reduction in toxicity (AIS &lt;0); 3% (three out of 101) had no change (AIS=0); and 27% (27 out of 101) an increase in overall toxicity. 62% (62 out of 101) of patients met the AIS minimally clinically important difference of ≤−10, but AIS did not correlate with glucocorticoid reduction or change in PROMs. Conclusion Mepolizumab resulted in substantial oral glucocorticoid reduction, but this did not correlate with reduction in oral glucocorticoid toxicity, which varies widely at the individual patient level. Oral glucocorticoid reduction is not a comprehensive measure of response to mepolizumab.
Pleiotropic effects of ursodeoxycholic acid
Authors: Yu.М. Stepanov, А.V. Salenko
Journal: GASTROENTEROLOGY (2021)

The article summarizes the literature data on the expansion of the range of application of ursodeoxycholic acid due to its various mechanisms of action. Almost 50-year history of the study of its properties has proven choleretic, litholytic, antiapoptotic, anti-inflammatory, immunomodulatory, cytoprotective, antifibrotic and hypocholesterolemic effects. In addition to the well-known functions of bile acids, their role has been shown as signaling, endocrine molecules that regulate glucose, lipids, and energy metabolism through pathways mediated by the activation of the nuclear receptor of the farnesoid X receptor and the cell surface G protein-coupled receptor, TGR5. The variety of nosological forms in which this substance can be successfully used is substantiated.
Implementation of new ECMO centers during the COVID-19 pandemic: experience and results from the Middle East and India
Authors: Ahmed A. Rabie, Mohamed H. Azzam, Abdulrahman A. Al-Fares, Akram Abdelbary, Hani N. Mufti, Ibrahim F. Hassan, Arpan Chakraborty, Pranay Oza, Alyaa Elhazmi, Huda Alfoudri, Suneel Kumar Pooboni, Abdulrahman Alharthy, Daniel Brodie, Bishoy Zakhary, Kiran Shekar, Marta Velia Antonini, Nicholas A. Barrett, Giles Peek, Alain Combes, Yaseen M. Arabi
Journal: Intensive Care Medicine (2021)
Canonical features of human antibodies recognizing the influenza hemagglutinin trimer interface
Authors: Seth J. Zost, Jinhui Dong, Iuliia M. Gilchuk, Pavlo Gilchuk, Natalie J. Thornburg, Sandhya Bangaru, Nurgun Kose, Jessica A. Finn, Robin Bombardi, Cinque Soto, Elaine C. Chen, Rachel S. Nargi, Rachel E. Sutton, Ryan P. Irving, Naveenchandra Suryadevara, Jonna B. Westover, Robert H. Carnahan, Hannah L. Turner, Sheng Li, Andrew B. Ward, James E. Crowe
Journal: Journal of Clinical Investigation (2021)

Broadly reactive antibodies targeting the influenza A virus hemagglutinin (HA) head domain are thought to be rare and to require extensive somatic mutations or unusual structural features to achieve breadth against divergent HA subtypes. Here we describe common genetic and structural features of protective human antibodies from several individuals recognizing the trimer interface (TI) of the influenza A HA head, a recently identified site of vulnerability. We examined the sequence of TI-reactive antibodies, determined crystal structures for TI antibody–antigen complexes, and analyzed the contact residues of the antibodies on HA to discover common genetic and structural features of TI antibodies. Our data reveal that many TI antibodies are encoded by a light chain variable gene segment incorporating a shared somatic mutation. In addition, these antibodies have a shared acidic residue in the heavy chain despite originating from diverse heavy chain variable gene segments. These studies show that the TI region of influenza A HA is a major antigenic site with conserved structural features that are recognized by a common human B cell public clonotype. The canonical nature of this antibody–antigen interaction suggests that the TI epitope might serve as an important target for structure-based vaccine design.
Building biointegration of Fe2O3–FeOOH coated titanium implant by regulating NIR irradiation in an infected model
Authors: Yang Xue, Jun Chen, Tiexin Ding, Mengting Mao, Shengbo Zhu, Jianhong Zhou, Lan Zhang, Yong Han
Journal: Bioactive Materials (2021)

Killing bacteria, eliminating biofilm and building soft tissue integration are very important for percutaneous implants which service in a complicated environment. In order to endow Ti implants with above abilities, multifunctional coatings consisted of Fe2O3–FeOOH nanograins as an outer layer and Zn doped microporous TiO2 as an inner layer were fabricated by micro-arc oxidation, hydrothermal treatment and annealing treatment. The microstructures, physicochemical properties and photothermal response of the coatings were observed; their antibacterial efficiencies and cell response in vitro as well as biofilm elimination and soft tissue integration in vivo were evaluated. The results show that with the increased annealing temperature, coating morphologies didn't change obviously, but lattices of β-FeOOH gradually disorganized into amorphous state and rearranged to form Fe2O3. The coating annealed at 450 °C (MA450) had nanocrystallized Fe2O3 and β-FeOOH. With a proper NIR irradiation strategy, MA450 killed adhered bacteria efficiently and increased fibroblast behaviors via up-regulating fibrogenic-related genes in vitro; in an infected model, MA450 eliminated biofilm, reduced inflammatory response and improved biointegration with soft tissue. The good performance of MA450 was due to a synergic effect of photothermal response and released ions (Zn2+ and Fe3+).
Increasing prevalence of childhood asthma and allergies in Eastern Europe but not in Sweden
Authors: H Vogt, A Breborowicz, Diana Dumitraşcu, Maia Gotua, Jolanta Kudzytė, Grzegorz Lis, Makke Luojus, L Nilsson, Vladimir Ognev, Alfred Priftanji, M Riikjarv, Bengt Björksten
Journal: Allergy (2007)
The Epic Sepsis Model Falls Short—The Importance of External Validation
Authors: Anand R. Habib, Anthony L. Lin, Richard W. Grant
Journal: JAMA Internal Medicine (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Abstract 10323: Growth Differentiation Factor-15 (GDF-15) is Involved in Muscle Atrophy of Patients With Cardiovascular Diseases
Authors: Toshiaki Nakajima, Hironaga Ogawa, Tatsuya Sawaguchi, Syotarou Obi, Shibasaki Ikuko, Yuusuke Takei, Satoshi Sakuma, Shigeru Toyoda, Masao Nishimura, Hirotsugu Fukuda, Teruo Inoue
Journal: Circulation (2019)

Introduction: Muscle atrophy and sarcopenia are predictors of ADL and survival in patients with cardiovascular diseases, and it increases the risk of complications and mortality when invasive treat...
A self-amplifying loop of YAP and SHH drives formation and expansion of heterotopic ossification
Authors: Qian Cong, Yuchen Liu, Taifeng Zhou, Yaxing Zhou, Ruoshi Xu, Caiqi Cheng, Hye Soo Chung, Meijun Yan, Hang Zhou, Zhiheng Liao, Bo Gao, Geoffrey A. Bocobo, Taylor A. Covington, Hyeon Ju Song, Peiqiang Su, Paul B. Yu, Yingzi Yang
Journal: Science Translational Medicine (2021)

A self-amplifying and propagating loop of YAP-SHH is a core molecular mechanism underlying diverse forms of heterotopic ossification.
Cutaneous Vasculitis in Systemic Lupus Erythematosus
Authors: Lu Yang, Yue-Ping Zeng
Journal: JAMA Dermatology (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal